Analyst Ratings Diverge on Healthcare Stocks as Moderna Faces Continued Pressure
核心洞察
Multiple analysts maintain Hold ratings on Moderna with price targets around $44-45, reflecting continued uncertainty about the company's prospects near its 52-week low.
Mediwound receives Strong Buy consensus from analysts with price targets suggesting over 100% upside potential from current trading levels.
Healthcare sector coverage shows mixed analyst sentiment, with some companies like BeOne Medicines (搜索) receiving strong buy recommendations while others face more cautious outlooks.
Healthcare sector analysts have issued divergent ratings on several prominent companies, with Moderna continuing to face lukewarm analyst sentiment while other biotech firms receive more optimistic assessments.
Moderna Maintains Hold Status Despite Low Valuations
UBS (搜索) analyst Michael Yee maintained a Hold rating on Moderna with a price target of $45.00, as the company's shares closed at $44.90, hovering near its 52-week low of $29.25. The analyst consensus remains at Hold with an average price target of $44.35, representing a 2.2% downside from current levels.
Bernstein analyst Courtney Breen also maintained a Hold rating on the mRNA vaccine maker, with shares trading at $46.06. Breen, who holds a 5-star analyst rating with an average return of 19.7% and an 88.5% success rate, focuses on major healthcare companies including Bristol-Myers Squibb, Merck & Company, and Gilead Sciences.
The continued Hold ratings reflect ongoing uncertainty about Moderna's growth prospects as the company navigates the post-pandemic landscape and works to diversify its pipeline beyond COVID-19 (搜索) vaccines.
Mediwound Receives Strong Buy Consensus
In contrast to Moderna's cautious analyst reception, Mediwound has garnered significantly more bullish sentiment from the analyst community. Michael Okunewitch from Maxim Group (搜索) maintained a Buy rating with a $30.00 price target, while the company's shares closed at $13.68, near its 52-week low of $12.78.
The wound care company has achieved a Strong Buy analyst consensus with a price target consensus of $29.00, implying a substantial 107.9% upside from current levels. Oppenheimer also maintained a Buy rating with a $32.00 price target, reinforcing the positive analyst sentiment surrounding the company's prospects.
Broader Healthcare Sector Coverage
The healthcare sector has seen extensive analyst coverage, with BeOne Medicines (搜索) receiving particularly strong support. J.P. Morgan (搜索) analyst Jessica Fye maintained a Buy rating on the company, which closed at $279.68 near its 52-week high of $287.88. The company has achieved a Strong Buy consensus with a price target of $393.49, representing a 36.8% upside.
Danaher (搜索) also received positive analyst attention, with Bank of America Securities (搜索) analyst Michael Ryskin maintaining a Buy rating and a $270.00 price target. The company trades with a Strong Buy consensus and a price target of $231.53, representing a 26.8% upside from its current price of $179.87.